Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.58 USD | -1.69% | -3.58% | +23.98% |
May. 13 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.98% | 2.17B | |
-5.86% | 12.09B | |
-4.87% | 8.21B | |
+5.47% | 5.74B | |
+30.13% | 5.64B | |
-9.89% | 4.16B | |
-58.20% | 2.88B | |
+8.97% | 2.69B | |
-5.19% | 2.33B | |
-6.23% | 1.86B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M